What is HC Wainwright’s Forecast for BTAI FY2024 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Equities researchers at HC Wainwright raised their FY2024 earnings estimates for BioXcel Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.48) for the year, up from their previous forecast of ($2.03). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.60) EPS.

Other equities analysts have also recently issued reports about the company. Bank of America restated an “underperform” rating and set a $0.25 price objective (down from $7.00) on shares of BioXcel Therapeutics in a research note on Tuesday, January 7th. Canaccord Genuity Group reduced their price target on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, January 6th.

BioXcel Therapeutics Stock Down 7.4 %

Shares of BioXcel Therapeutics stock opened at $0.29 on Monday. The business has a 50-day moving average price of $0.38 and a 200 day moving average price of $0.57. BioXcel Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $4.17. The firm has a market cap of $14.14 million, a P/E ratio of -0.13 and a beta of -0.01.

Institutional Trading of BioXcel Therapeutics

A hedge fund recently bought a new stake in BioXcel Therapeutics stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 30,295 shares of the company’s stock, valued at approximately $39,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.08% of BioXcel Therapeutics at the end of the most recent quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.